C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation by unknown
C3a Is  a  Chemotaxin  for Human  Eosinophils  but Not 
for Neutrophils.  I.  C3a Stimulation  of Neutrophils  Is 
Secondary  to Eosinophil  Activation 
By Pamela J. Daffern, Philippe H. Pfeifer, Julia A. Ember, 
and Tony E. Hugli 
From the Department of Immunology, The Scripps Research Institute, La Jolla, California 
92037 
Summary 
Inflammatory action of the potent chemotaxin C5a has been well characterized  on a variety of 
human cell types, including neutrophils, monocytes, basophils, and eosinophils. The cellular effects 
of C3a are less well defined. Contradictory reports have been published for C3a activation of 
neutrophils. Recent reports that C3a activates both basophils and eosinophils prompted us to 
reinvestigate the effects of C3a stimulation on eosinophils. We hypothesized that C3a activation 
of eosinophils, cells that are present in most neutrophil preparations, might lead to neutrophil 
activation.  Using neutrophils of 98% purity, we observed no evidence of cellular activation after 
stimulation with either C3a, recombinant human C3a (rhC3a), or the synthetic C3a analogue 
C3a  57-77,  Y57.  Eosinophils purified  to  >98%  purity  displayed  concentration-dependent 
polarization, chemotaxis, and enzyme release by stimulation with C3a, rhC3a, and the synthetic 
C3a  analogue.  An inactive  form of C3a,  C3aaes^rg,  failed  to stimulate either eosinophils or 
neutrophils. Using neutrophil preparations containing 5-9% eosinophils, up to 20% of neutrophils 
became polarized after exposure to C3a. Likewise, we demonstrated that supernatant from C3a- 
stimulated eosinophils promotes neutrophil chemotaxis. Eosinophil polarization experiments were 
repeated in the presence of antibody to the C5a receptor (C5aR) to show that C3a and C5a 
interact with different receptors. C3a activates eosinophils in the presence of anti-C5aR antibody 
at concentrations that fully block C5a activation. We conclude that eosinophils are directly activated 
by either C3a or C5a, whereas C3a failed to activate neutrophils. C3a acts on eosinophils via 
a receptor that is distinct from C5aR. Since neutrophils are indirectly stimulated by C3a, eosinophils 
contaminating neutrophil preparations may explain  earlier  reports that C3a activates  human 
neutrophils. 
B 
iologic responses to complement-derived  anaphylatoxins 
C3a and C5a have been studied in a variety of human 
and animal cells. C5a is a potent activator  of many human 
cell types and induces in vivo cellular responses such as neu- 
tropenia  and  leukocytosis  (1). C5a  is  a  highly  potent 
chemotaxin, and it stimulates the release of hydrolytic granular 
enzymes, bioactive lipids, and superoxide anions from neu- 
trophils (2-4).  In addition, C5a is one of the most potent 
chemotactic agents known for eosinophils (5-10).  Recently, 
a C5a receptor has been characterized  on eosinophils (11). 
The eosinophil receptor for C5a appears to be unique from 
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the  neutrophil  C5a  receptor  (C5aR), 1  having  different 
binding characteristics and displaying a greater apparent mass 
based on cross-linking studies. 
In contrast to well-characterized responses to C5a by many 
types of cells, there are few studies of responses from purified 
populations of human leukocytes to C3a.  Convincing evi- 
dence for C3a activation exists primarily for guinea pig platelets 
(12, 13). However,  nonspecific mechanisms of cellular acti- 
vation appear to account for the stimulatory responses of rat 
mast cells, and perhaps other cell types, to C3a (14, 15). C3a 
effects on human granulocytic cell types remain controversial. 
Earlier studies reporting C3a-induced degranulation, aggre- 
gation, and chemotaxis of human neutrophils (16-19) have 
been criticized for possible  contamination by C5a and for 
1 Abbreviations used in this paper: C3aR,  C5aR,  C3a or C5a  receptor, 
respectively; EBSS, Earl's balanced salt solution; EPO, eosinophil peroxidase; 
MOPS, morpholinopropane sulfonic  acid; rhC3a, recombinant human C3a. 
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the response  (20,  21).  More recently,  12SI-labeled C3a was 
used to demonstrate binding to human neutrophils and C3a- 
dependent  increases  in  cytosolic  calcium  (22-24).  These 
findings contradict low level or negligible binding to neu- 
trophils of either radiolabeled or fluorescein-labeled C3a that 
have been reported by other investigators (25,  26). 
However, recent studies report that granulocytes other than 
neutrophils have functional C3a receptors (C3aRs). Binding 
of 12sI-C3a to basophils has been shown (25). Histamine re- 
lease occurs after C3a stimulation of mixed leukocytes (27), 
a response that is augmented by priming with IL-3 or GM- 
CSF (28). In addition, a basophilic leukemia cell line shows 
similar C3a-binding  and functional responses  (29). 
There is increasing evidence that eosinophils may bear func- 
tional C3aRs.  Radiolabeled C3a has been demonstrated to 
bind to eosinophils and to activate the respiratory burst (30, 
31).  Both C3a and CSa stimulate release of eosinophil cat- 
ionic protein and induce increased intracellular calcium levels 
(32, 33). Based on these reports, we hypothesized that C3a 
should induce eosinophil polarization, chemotaxis, and granule 
release. A second hypothesis was that C3a-activated eosinophils 
may release factors capable of stimulating a neutrophil re- 
sponse. Consequently, the presence of small numbers of eo- 
sinophils in neutrophil preparations, rather than direct acti- 
vation of neutrophils by C3a, could explain previous reports 
of apparent  direct neutrophil activation by C3a. 
Materials  and Methods 
Reagents.  Dextran 70 was supplied by Baxter Healthcare Corp. 
(Deerfield, IL). Ficoll and Percoll were purchased from Pharmacia 
Inc. (Piscataway, NJ). Hypaque was supplied by Sanofi-Winthrop 
Pharmaceuticals  (New York, NY). Earle's balanced salt solution 
(EBSS) was supplied by GIBCO BRL (Gaithersburg,  MD). BSA, 
guaiacol, morpholinopropane sulfonic acid (MOPS), cytochalasin B, 
p-nitrophenyl-~8-D-glucuronide, and eosino Y were purchased from 
Sigma Chemical Co. (St. Louis, MO). Goat anti-mouse IgG-coated 
magnetic beads and a magnetic separation unit were purchased from 
Advanced Magnetics, Inc. (Cambridge, MA). Unconjugated mouse 
anti-human CD16 monoclonal antibodies were purchased from ei- 
ther Biosource International (Camarillo, CA) or Chemicon Inter- 
national, Inc. (Temecula, CA). 6.5-mm Transwell plates were pur- 
chased from Costar Corp.  (Cambridge,  MA). Triton X-100 was 
supplied by Pierce Chemical Co. (Rockford, IL). RPMI-1640 was 
purchased from Bio-Whittaker (Walkersville, MD). A 10-ml pyc- 
nometer was purchased from Kimble Science Products (Vineland, 
NJ). ILIA kits for CSa assays  were purchased from Amersham Corp. 
(Arlington Heights, IL). The synthetic C3a analogue C3a 57-77, 
Y57 (peptide sequence YCNYITELRRQHARASHLGLAR) was 
purchased from Peninsula Laboratories, Inc. (Belmont, CA). Recom- 
binant human C3a (rhC3a) was a gift from Dr. Yoshihiro Fukuoka 
(Tohoku University,  Sendai, Japan)  (34). Polyclonal antibody to 
the C5aR (CD88) was generated as described by Morgan et al. (35). 
Purification of C3a and C5a.  Human C3a and CSa were purified 
by the method of Hugli et al. (36). Human C3a prepared in this 
fashion was shown to contain 1 part per million C5a as measured 
by RIA. C3a~ s was obtained by treating the highly purified C3a 
with 1% (wt/wt) carboxypeptidase B for 30 min at 37~  in am- 
monium bicarbonate buffer at pH 8.0. Concentrations of C3a, C5a, 
and rhC3a were determined by amino acid analysis. 
NeutrophilPreparation.  Neutrophils were isolated from periph- 
eral blood of healthy human donors according to the method of 
Ferrante  and  Thong  (37,  38).  Blood was  drawn  into  EDTA- 
containing syringes to achieve  a final concentration of 10 mM EXYFA. 
35 ml of whole blood was carefully layered over 15 ml of Ficoll- 
Hypaque (density of 1.106 g/ml) in a 50-ml conical tube and cen- 
trifuged at 700 g for 25 min. The granulocyte fraction was recov- 
ered from between the mononuclear cell layer and the red cell pellet. 
The total granulocyte count was obtained through manual counting 
using Turk stain. The percentage of eosinophils in the granulocyte 
fraction was determined by staining the cells with 0.1 part of a 
solution of 0.1% eosin Y in 10% acetone and counting 200 cells 
in a hemocytometer.  The granulocyte fraction obtained in this 
fashion contained from 2 to 9% eosinophils.  Only the top half 
of the visible neutrophil band was collected for obtaining highly 
purified neutrophils.  This procedure resulted in neutrophil prepa- 
rations of >98% purity as assessed  by eosin staining. The remaining 
granulocyte fraction was enriched for normodense eosinophils and 
could be further purified as described below. The nentrophils were 
washed twice in EBSS containing 10 mM MOPS at pH 7.35 be- 
fore resuspension  in the buffer used for the assays. 
Eosinophil Preparation.  Enriched preparations of eosinophils were 
obtained  from the blood  of normal donors using one  of two 
methods. Eosinophils were obtained by Percoll density gradient sepa- 
ration following a modification of the procedure  described  by 
Gartner (39). Briefly, isotonic Percoll was prepared using a 10 x 
solution of PBS-BSA-citrate  and then diluted with PBS-BSA- 
citrate solution to achieve specific gravities of 1.094,  1.085, and 
1.077 g/m1, respectively (as measured with a pycnometer at 20~ 
3 ml of each Percoll suspension were carefully layered on top of 
one another in a 15-ml conical polypropylene tube before applying 
the cell suspension (3 ml of PBS solution containing <200  x  106 
cells). The tubes were spun at 1,000 g for 20 min at 20~  The 
cells were collected from just below the interface between the two 
upper Percoll solutions (i.e., specific gravities of 1.077 and 1.085) 
down to the red cell pellet.  This fraction was further purified by 
negative selection using a modification of the anti-CD16  method 
described  by Hansel et  al.  (40). The granulocyte mixture was 
resuspended in RPMI-1640 containing 10% FCS. The neutrophil- 
specific mouse anti-CD16  antibody was added (10 gl/10 miUion 
neutrophils)  and  incubated  for  30  rain  at  4~  Anti-mouse 
IgG-coated magnetic beads (60 particles per neutrophil) were added 
to this mixture and incubated at room temperature for 30 rain. 
The beads were then removed with the adherent neutrophils by 
magnetic separation. The remaining eosinophils were >98% pure 
as assessed by eosin staining.  Alternatively,  blood was processed 
as described above for the neutrophil isolation  procedure  using 
Ficoll-Hypaque. The eosinophil-enriched  neutrophil fraction was 
further purified by negative selection of neutrophils as described 
above. 
Polarization Assay.  Neutrophil polarization assays were  per- 
formed according to a modification of the procedure described by 
Smith et al. (41). Nentrophils were suspended at 2  x  106 cells/ml 
in EBSS containing 10 mM MOPS.  The cells were incubated at 
37~  for 0.5-40 rain with an equal volume of the stimulant at 
varying concentrations.  The reaction was terminated by addition 
of an ice-cold solution of 2.5% glutaraldehyde  and 0.04% eosin 
in 0.9% saline. 200 cells from each aliquot were examined microscop- 
icaUy at a magnification of 400. Cells of atypical shape (i.e., other 
than spherical) were scored as polarized, and results were expressed 
as percentage of cells polarized.  The percentage  of eosinophils in 
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bined staining/fixation  technique. 
Polyclonal  neutralizing antibody to the C5aR was affinity  purified 
and  used  for C5aR  inhibition  experiments  (35). Cells (4  x 
106/ml) and an equal volume of anti-CSaR  antibody (10/~g/ml) 
were incubated for 15 min at room temperature. Polarization was 
assessed after addition of an equal volume of  stimulant as described 
above. 
Chemotaxis Assay.  Chemotaxis assays were performed in 6.5- 
mm TransweU  plates using a modification of  the procedure of  Ember 
et al. (42). The wells were filled with 600 ~1 of the desired dilution 
ofchemotactic factor in EBSS-MOPS-I% BSA solution. Cells were 
suspended at 3 million/ml,  100-/A aliquots were pipetted onto the 
filter, and the plates were incubated for 2 h at 37~  Cells from 
the lower compartment were collected, pelleted, and fixed in eosin- 
containing  glutaraldehyde  solution,  and  then  counted  with  a 
hemocytometer. 
Eosinophil Peroxidase Assay.  Purified eosinophils were resus- 
pended in EBSS-MOPS-I%  BSA solution  at 5  x  106 cells/m1. 
The cell suspension was preincubated with 5/~g/ml of  cytochalasin 
B at 37~  for 10 min and then 100-/A aliquots were added to an 
equal volume of stimulant in Eppendorf tubes. After incubation 
at 37~  for 1 h,  the tubes were centrifuged and placed on ice. 
Eosinophil  peroxidase  (EPO)  activity  was  measured  through 
guaiacol oxidation (43). Briefly, 1.2 ml of 1 M KH2PO4/K2HPO4 
(pH 7.0),  174/A of guaiacol, 4.6/A of 30% H202,  and 115 ml 
of water were mixed. 50 #1 of eosinophil supernatant was added 
to 3 ml of this solution in polystyrene cuvettes. The change in ex- 
tinction (AE) at 470 nm is measured over 1 min. With an e470  - 
26.6 mM-1 cm-1,  activity (in units per liter) was calculated as 
A  =  [AE  x  V,  x  4,000] /  [6470  x  IT,  x  t] 
where  V, is the total volume in microliters, Vo is the volume of 
the analyzed sample in microliters, and t is the time in minutes. 
EPO activity is expressed as the percentage of total cell peroxidase 
after cell lysis with 3% acetic acid in  1% Triton X-100. 
l?-Glucuronidase Release Assay.  B-Glucuronidase released from 
stimulated cells was determined as described by Schr6der et al. (44). 
Neutrophils  were  suspended in  EBSS with  1%  BSA  at  10  x 
106/ml. After a 10-min preincubation with 5 ~g/ml cytochalasin 
B, 100/A of ceUs was stimulated for I h at 37~  The supernatant 
was incubated with an equal volume of  0.01 M p-nitrophenyl-B-D- 
glucuronide for 18 h. The reaction was quenched by addition of 
an equal volume of 0.4 M glycine buffer, pH 10.0. Color intensity 
was read at 405 nm in a Titertec Multiscan/340 ELISA reader (Lab- 
systems, Inc., Marlboro, MA). 3-glucuronidase release is expressed 
as the percentage of total cell enzyme content after cell lysis with 
0.2% Triton X-100. 
Results 
C3a- and rhC3a-induced Polarization of Eosinophils and Neu- 
troFhik  Polarization results for highly purified eosinophil 
and neutrophil preparations stimulated by C3a and rhC3a 
are shown in Fig.  1. C3a induces polarization of up to 70% 
of the eosinophils with an EDs0 of 30 nM C3a.  An EDs0 
of <100 pM was observed for rhC3a. Likewise,  the synthetic 
C3a analogue C3a 55-77, Y57 gave similar polarization re- 
sponses,  though with ,,o10%  of the potency of the natural 
factor (data not shown). In control experiments, up to 70% 
of the eosinophils and 95% of the neutrophils were polar- 
ized after stimulation with 0.5 nM C5a, but concentrations 
100 
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Figure  1.  Polarization  of highly purified human eosinophils  and neu- 
trophils in response  to C3a, rhC3a, C3a~,^rs, and C5a. Highly purified 
neutrophils or eosinophils were  incubated with various concentrations  of 
stimulant (as indicated on the x axis) at 37~  for 30 rain. Polarization 
is expressed  as percentage  of  the total  number  of  cells  counted.  Mean  values 
_+ SE (n = 7). Note that C3a stimulates eosinophils  but not neutrophils. 
of rhC3a as high as  1 /zM failed  to stimulate neutrophils. 
Neither cell type was activated after incubation with up to 
2/~M C3aae,^~g. 
Time Course of Cell Activation by C3a and C5a.  Fig. 2 A 
depicts the time course for neutrophil polarization at various 
C5a concentrations. Neutrophils display maximal (>99%) 
and sustained polarization within 30 s of stimulation at C5a 
concentrations t>0.5 nM.  Only transient responses are seen 
at lesser concentrations; however, both responses occur within 
seconds of exposure. 
Fig. 2 B depicts eosinophil shape changes using similar con- 
centrations of C5a.  Unlike neutrophils, eosinophils do not 
permanently polarize at C5a concentrations <0.5 nM. How- 
ever, biphasic responses occur between 2 and 20 min at C5a 
concentrations between 0.5 and 2 nM.  Sustained polariza- 
tion of ,'o70% of the eosinophils was achieved at C5a con- 
centrations I>5 nM. 
The response of eosinophils to C3a is shown in Fig.  2 C. 
A markedly delayed pattern of activation is apparent when 
compared with C5a activation of either eosinophils or neu- 
trophils. A maximum of 70% of the eosinophils are polar- 
ized after 20 min by 100 nM C3a. 
C3a-induced Chemotaxis of Eosinophils.  Chemotactic re- 
sponses of eosinophils and neutrophils to C3a and C3a 57- 
77,Y57  are  shown  in  Fig.  3.  Concentration-dependent 
chemotactic responses of eosinophils were observed for C3a 
and the C3a analogue as depicted in Fig. 3 A. The EDs0 for 
chemotaxis to C3a is 100 nM and for the C3a analogue is 
1 #M (data not shown). These results also reveal that highly 
purified neutrophils were not stimulated by either C3a or 
the analogue C3a 57-77,Y57 up to the indicated maximal 
concentrations.  In control experiments, the migratory re- 
sponses of both cell types to C5a was examined. As shown 
in Fig.  3 B,  neutrophils show maximal responses of 55% 
of the cells migrating to 5 nM C5a, with an EDs0 of 1 nM 
C5a. 40% of the eosinophils were induced to migrate by 0.3 
nM C5a, a level similar to that which induced detectable polar- 
ization. These results suggest that the potency of C5a for 
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Figure  2.  Time course of cell activation by C3a and C5a. Cells were 
incubated with specified  concentrations of stimulant,  and aliquots were 
removed at the indicated times. Experimental conditions are the same as 
in Fig. 1. (.4) Neutrophils polarization induced by CSa versus time (IB). 
(B) Eosinophil polarization by C5a versus time (@). (C) Eosinophil polar- 
ization induced by C3a versus time (&). Results are expressed as mean 
_+  SE (n  =  9).  Note the differences in rates  of activation. 
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chemotaxis of eosinophils is ~ 10 times greater than for neu- 
trophils. 
Enzyme Release by C3a, rhC3a, and C5a.  C5a stimula- 
tion of either eosinophils or neutrophils leads  to release of 
~-glucuronidase, as shown in Fig. 4 A. Both C3a and rhC3a 
stimulated concentration-dependent release of/~-glucuronidase 
from eosinophils but not from neutrophils.  The corresponding 
EDs0 for C3a and rhC3a is 100 nM,  although the recom- 
binant form of C3a appears  slightly more potent. The syn- 
thetic C3a analogue was also weakly stimulatory for promot- 
ing enzyme release from eosinophils (data not shown), while 
C3a~,^,g was inactive for both ceil types. Fig.  4 B indicates 
that eosinophil peroxidase was released after stimulation with 
C3a, rhC3a, or C5a but not with C3a~^,g. C5a was 50-100 
times more potent than C3a for enzyme release. 
Effects of C3a-stimulated  Eosinophils on Neutrophil Responses. 
Studies reporting that C3a activates neutrophils have gener- 
ally failed to indicate the purity of their preparations. Others 
report purity of 90-96% neutrophils, and the contaminating 
cells are stated to be eosinophils.  However, differential counts 
of Wright-Giemsa-stained whole blood or granulocyte prepa- 
rations are known to be inaccurate and may routinely un- 
derestimate eosinophils (45). Using published neutrophil prep- 
aration methods, as well as the neutrophil isolation procedure 
Figure  3.  Chemotactic response of eosinophils and neutrophils to C3a 
and to the C3a analogue 57-77,Y57.  Eosinophils and neutrophils were iso- 
lated, and 3  x  105 cells were added to the upper chamber. The chemoat- 
tractants were added to the lower chamber. Migration is expressed as the 
percentage of the total number of cells added to the chamber. Mean values 
_+ SD for four experiments are shown. (A) Chemotaxis to C3a and syn- 
thetic C3a analogue.  (B) Chemotactic response to CSa.  Note that C5a 
induced migration  of both  cell types,  while C3a induced migration of 
eosinophils only. 
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Figure  4.  Release of/3-glucuronidase and EPO by C3a, rhC3a, C5a, 
and C3aa~^~g. Purified neutrophils (10 6) or eosinophils (0.5 x  10  6) were 
incubated with specified  concentrations of the agonist as indicated on the 
x axis. After 1 h, supernatants were assayed for enzyme content. Mean 
values _+ SE (n  =  5) are expressed as percentage of total cell content of 
enzyme released after cell lysis. (.4) 13-Glucuronidase  release induced by 
C3a and C5a from neutrophils and eosinophils. (B) EPO release by C3a 
and C5a from eosinophils. 
described in Materials and Methods,  the yield of eosinophils 
in the granulocyte fraction from normal donors is 2-9%  in 
our hands. 
To test the hypothesis that eosinophils are activated by C3a 
and then secondarily activate neutrophils, the two following 
studies were performed on granulocyte preparations containing 
varying percentages of eosinophils. First, we stimulated gran- 
ulocyte preparations containing indicated percentages of eo- 
sinophils for various intervals with a constant concentration 
of C3a (100 nM). Second, we stimulated granulocyte prepa- 
rations  containing  5-9%  eosinophils  with  increasing  con- 
centrations of C3a.  Fig.  5 A  shows that C3a-induced  neu- 
trophil polarization depends on the eosinophil concentration. 
Using  granulocyte preparations  that  contain  >5%  eosino- 
phils, the neutrophils undergo C3a-induced polarization. Polar- 
ization of neutrophils by C3a follows a delayed time course 
such as that depicted for eosinophils in Fig. 2  C  rather than 
the rapid response-typical of C5a-induced neutrophil activa- 
tion (Fig. 2 A).  Neutrophil preparations containing 3% or 
less eosinophils were not activated by C3a, even though the 
eosinophils  themselves  were  polarized.  When  neutrophil 
preparations containing >15%  eosinophils were stimulated 
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Figure  5.  Eosinophil-dependent  neutrophil activation  by C3a. Neutro- 
phils containing 2-9% eosinophils were collected from normal donors. 
The cells were suspended without further purification or hypotonic lysis 
in EBSS/MOPS solution at 2  x  106/ml, and 125 #1 of cells was added 
to an equal volume of stimulant. Cells were fixed  and stained using a cold 
solution of eosin and glutaraldehyde  to differentiate  between neutrophils 
and eosinophils. Buffer control values were subtracted from the values at 
the relevant time points. (-4) Time course for stimulation of the granulo- 
cytes with 100 nM C3a. The granulocyte  preparations contain various per- 
centages of eosinophils as marked on the right side of the figure. Mean 
values _+ SD (n  =  3) are shown. (B) Increasing concentrations of C3a 
were incubated for 40 min with neutrophil preparations containing 5-9% 
eosinophils. Mean values _+  SE (n  =  7) are shown. 
by C3a,/>90%  of the neutrophils were polarized (data not 
shown).  Fig.  5 B  shows  the effect of increasing concentra- 
tions  of C3a  on neutrophil preparations  containing  5-9% 
eosinophils. A concentration-dependent response to C3a stim- 
ulation is apparent, with up to 25% of neutrophils activated 
by  1 #M  C3a  after 40 rain. 
To extend these observations, we examined whether C3a 
stimulation of eosinophils would induce neutrophil chemo- 
taxis.  Neutrophil  migration  from  the  upper  to  the  lower 
chamber was assessed when eosinophils and/or C3a were added 
to the lower chemotaxis chamber. Neutrophils failed to mi- 
grate when either C3a or unstimulated eosinophils alone were 
placed in the lower chamber, as shown in Fig.  6. However, 
a concentration-dependent chemotaxis of neutrophils occurred 
when C3a-stimulated eosinophils were present in the lower 
chamber. Additionally, neutrophil migration to suboptimal 
levels of C5a was  enhanced by the presence of eosinophils 
in the lower chamber. The combination of C5a and eosinophils 
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Figure 6.  Eosinophil-induced  chemotaxis ofneutrophils. Highly  purified 
eosinophils or neutrophils were suspended in EBSS with 1% BSA at 107 
cells/ml. In addition to the chemoattractant, 106 eosinophils or equal 
volume of buffer were added to the lower chamber. Neutrophils (5  ￿ 
106) were added to the upper chamber and incubated for 90 rain at 37~ 
Neutrophils migrating into the lower chamber were then counted as de- 
scribed. C3a- and CSa-induced migration in the presence or absence of 
eosinophils is shown. A representative experiment (out of four) is shown 
and indicates that eosinophils enhanced the chemotactic response to C3a 
and C5a. Note the difference  in numbers of eosinophils  and neutrophils used. 
resulted in migration of 45 % of the neutrophils, a migratory 
response requiring  five times higher  level of C5a. 
Evidence  for a C3aR-specific Response.  Previous reports in- 
dicated cross-densensitization  between C3aR and C5aR using 
COOH-terminal C5a analogues in guinea pig platelets (46). 
It was suggested that COOH-terminal  CSa analogues, but 
not natural  C5a,  interact with receptors for both C3a and 
CSa on these cells (46). Experiments were repeated with rhC3a 
in both the presence and absence of neutralizing  antibody 
to the C5aR to rule out the possibility that cross-reactivity 
between C3a and both  C3aR and CSak could have been 
responsible for C3a-induced activation of eosinophils. Incu- 
bation of eosinophils or neutrophils with antibody to C5aR 
does not activate the cells (Fig.  7). Preincubation of neutro- 
phils or eosinophils with anti-CSaR antibody did inhibit ac- 
tivation by CSa, although eosinophil stimulation by rhC3a 
was unaffected by the antibody. These results indicate that 
C3a interacts with a unique receptor on eosinophils, and its 
effects are not the result of cross-reactivity with the C5aR. 
Discussion 
We present evidence for activation of eosinophils by C3a, 
which resulted in polarization,  chemotaxis, and degranula- 
tion (Fig.  1-3).  Our results appear to establish that highly 
purified neutrophils lack these responses to C3a. The failure 
of recombinant C3a or synthetic C3a analogues to activate 
neutrophils suggests that earlier reports of neutrophil activa- 
tion by C3a can be explained either by trace contamination 
of the native C3a by CSa (20, 21) or by C3a activation of 
eosinophils present in neutrophil preparations. Evidence that 
activation of eosinophils is receptor specific is strengthened 
by an inability of C3a~,^rs tO activate eosinophils and also 
by the fact that eosinophils are activated by rhC3a in the pres- 
ence of neutralizing  antibody to C5aR (Fig.  7).  Like C3a, 
C3a~,^, s is strongly cationic but lacks the COOH-terminal 
100- 
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Figure  7.  Anti-CSaR  antibody  inhibits C5a- but not C3a-induced  pohr- 
ization of eosinophils. Either eosinophils or neutrophils were incubated 
with control IgG or affinity-purified  antibody to the C5aR (anti-CSaR) 
for 15 min at 20~  The cell suspensions were then incubated with 0.5 
nM CSa or 100 nM C3a for 30 min at 37~  and polarization was as- 
sessed. Mean values + SE for five experiments indicate that anti-C5aR 
did not inhibit C3a activation of the eosinophils. (Asterisks indicate 
significant inhibition compared with C5a alone.) 
arginyl residue required for binding to the receptor. There- 
fore, nonspecific polycationic activation, such as that observed 
with rat mast cells (14, 15), does not account for C3a-induced 
eosinophil  activation. 
Guinea pig platelets are the only other cell type for which 
there is strong evidence for both C3a and C5a receptors and 
activation (12, 13). While the intact natural factors C3a and 
C5a do not show cross-desensitization in guinea pig platelets, 
COOH-terminal analogues of C5a have been reported to in- 
teract with both C3aR and CSaR (46). These data indicate 
that C3a and C5a receptors lack selectivity for the C3a and 
C5a COOH-terminal  effector sequences (46).  Using  site- 
directed mutagenesis, a hybrid C5a-C3a molecule was con- 
structed by replacing three of the five COOH-terminal residues 
in C5a with the corresponding COOH-terminal residues of 
C3a (i.e.,  MQLGR is replaced by LGLAR) (47).  Binding 
studies indicated that  the hybrid C5a-C3a molecule binds 
to receptors for both C3a and C5a on guinea pig platelets. 
Cellular activation studies, on the other hand, indicated that 
the COOH-terminal residues in the C3a ligand (i.e., LGLAR) 
determine specificity for interaction  with the C3aR, while 
the C5aR appears more permissive (47). We believe that our 
data indicate that C3a and CSa each use a unique receptor 
for eosinophil  activation. 
The potency of native C3a for eosinophil activation is 20-30- 
fold less than that for CSa on a molar basis (Fig.  1-4).  On 
the other hand, levels of C3 in plasma are 20-30-fold greater 
than C5 levels (48). Therefore, in situations where comple- 
ment is activated, the potential activities of C3a and C5a on 
eosinophils are nearly equivalent.  The enhanced potency of 
rhC3a compared with the native factor can only be explained 
by the  presence  of an  additional  methionyl  group  at  the 
NH2 terminus  of rhC3a  (34). 
The time course for C3a-induced polarization of eosinophils 
is significantly  slower than CSa activation in either eosinophils 
or neutrophils  (Fig.  2, A-C).  This  suggests that  C3a may 
stimulate eosinophils to produce secondary mediators, which 
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known that eosinophil products can activate a variety of cell 
types, including the neutrophil. The time course for neutro- 
phil activation that was observed with C3a suggests that the 
activating factor(s) is either preformed or rapidly synthesized 
by the eosinophil. Major basic protein is found in eosinophil 
granules and has been shown to cause noncytotoxic neutro- 
phil activation (49) and upregulation of CR3 and p150,95 
expression (50). Reports have demonstrated the release of  both 
preformed and newly synthesized IL-8 from calcium iono- 
phore-stimulated eosinophils (51, 52), making this cytokine 
a potential candidate for neutrophil activation. Platelet ac- 
tivating factor, which is rapidly synthesized and released ex- 
tracellularly from eosinophils (53),  is a potent activator of 
both eosinophils and neutrophils (5, 6, 8-10, 54, 55). Other 
eicosanoid  products  made  by  eosinophils,  such  as  8,15- 
dihydroxyeicosatetraenoic  acid, have also been reported to have 
chemotactic activity for neutrophils (56, 57).  Hence, there 
are many possible explanations for the ability of eosinophils 
to stimulate and enhance neutrophil function. 
The in vitro effects of this interaction between eosinophils 
and neutrophils could explain the inconsistencies in previous 
reports suggesting that C3a can activate neutrophils (16-19, 
22-24).  Even small numbers of eosinophils in a neutrophil 
preparation activate a significant number of neutrophils if the 
C3a concentrations are su~ciently high (>1/~M). However, 
the potential in vivo role of C3a in disease states  remains 
speculative. Systemic consequences of complement activation 
may be regulated by the carboxypeptidases in plasma and on 
cell membranes that cleave COOH-terminal arginine from 
both C3a and CSa to produce C3a~  s and CSaa~g, respec- 
tively (58,  59).  While CSa~g  retains up to  50%  of its 
potency as a cell activator, the desArg form of C3a retains 
little if any residual activity (60). This implies that C3a may 
be active only at extravascular sites, where there is relatively 
less exposure to these carboxypeptidases. 
Several types of diseases are commonly associated with pe- 
ripheral blood or tissue eosinophilia. These include allergic 
disorders, parasitic or other infectious diseases, selected cuta- 
neous and pulmonary diseases, and connective tissue diseases 
(61). Connective tissue disorders are known to be associated 
with complement activation and are occasionally accompa- 
nied by striking levels of peripheral blood or tissue eosinophilia 
(62).  It is not yet clear how or why the inflammatory re- 
sponse in these diseases favors eosinophilic versus neutrophilic 
infiltrations. In addition to connective tissue disorders, depo- 
sition of C3 with eosinophilic infiltrates has been demon- 
strated in lesional skin biopsies from patients with the skin 
diseases pemphigoid and herpes gestationis (63). The role of 
C3a in either of these disorders has not been previously ex- 
amined. However, the potential role of both C3a and C5a 
in mediating eosinophilic inflammation merits further inves- 
tigation in light of our results suggesting that C3a is able 
to selectively activate eosinophils. 
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